Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.22 (
cdc2
)
8,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The TrkA receptor tyrosine kinase induces death in medulloblastoma cells via an interaction with the
cerebral cavernous malformation 2
(
CCM2
) protein. We used affinity proteomics to identify the germinal center kinase class III (GCKIII) kinases STK24 and
STK25
as novel
CCM2
interactors. Down-modulation of
STK25
, but not STK24, rescued medulloblastoma cells from NGF-induced TrkA-dependent cell death, suggesting that
STK25
is part of the death-signaling pathway initiated by TrkA and
CCM2
.
CCM2
can be phosphorylated by
STK25
, and the kinase activity of
STK25
is required for death signaling. Finally,
STK25
expression in tumors is correlated with positive prognosis in neuroblastoma patients. These findings delineate a death-signaling pathway downstream of neurotrophic receptor tyrosine kinases that may provide targets for therapeutic intervention in pediatric tumors of neural origin.
...
PMID:STK25 protein mediates TrkA and CCM2 protein-dependent death in pediatric tumor cells of neural origin. 2278 92